These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34215653)

  • 1. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
    Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
    J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
    Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
    Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway.
    Canaday DH; Ziebold C; Noss EH; Chervenak KA; Harding CV; Boom WH
    J Immunol; 1999 Jan; 162(1):372-9. PubMed ID: 9886409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
    Sinnathamby G; Zerfass J; Hafner J; Block P; Nickens Z; Hobeika A; Secord AA; Lyerly HK; Morse MA; Philip R
    Clin Exp Immunol; 2011 Mar; 163(3):324-32. PubMed ID: 21175594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
    Jost C; Darowski D; Challier J; Pulko V; Hanisch LJ; Xu W; Mössner E; Bujotzek A; Klostermann S; Umana P; Kontermann RE; Klein C
    MAbs; 2020; 12(1):1840709. PubMed ID: 33136521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
    Yao X; Matosevic S
    Immunol Lett; 2024 Aug; 268():106881. PubMed ID: 38810886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
    Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
    PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
    Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells.
    Seo MJ; Kim GR; Son YM; Yang DC; Chu H; Min TS; Jung ID; Park YM; Han SH; Yun CH
    Mol Immunol; 2011 Sep; 48(15-16):1744-52. PubMed ID: 21632112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
    Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.